Neoepitopes

December 15, 2025, 11:16 AM

In 2025, neoepitopes continue to play a crucial role in cancer immunotherapy. The development of personalized neoepitope-based cancer vaccines, such as NECVAX-NEO1, is a significant advancement. This vaccine utilizes AI prediction to identify and rank patient-specific neoepitopes, aiming to elicit robust and specific immune responses against tumor cells. The clinical trial results indicate promising immune responses, with 83% of patients achieving stable disease at the end of the treatment period. This highlights the potential of neoepitopes in personalized cancer treatment, offering a targeted approach to combat cancer

What Is a Neoepitope and Its Role in Cancer Therapy? - Biology Insights

Neoepitopes are the direct result of genetic changes, called somatic mutations, that occur within tumor cells. These alterations to the DNA are not inherited but accumulate in cells over a person’s lifetime. When a mutation occurs in a protein-coding region of DNA, it can lead to the production of an altered protein not found in healthy cells.

Once these altered proteins are made, they are broken down inside the cell into smaller pieces called peptides. These peptides are then transported to the cell’s surface and displayed by specialized molecules known as the major histocompatibility complex (MHC). When a mutated peptide is presented on an MHC molecule, it forms a neoepitope.

Because these genetic mutations are specific to the cancer, the resulting neoepitopes are also exclusive to those cancer cells. They serve as highly specific markers, providing a clear distinction between cancerous and normal tissues. The number of mutations a tumor has, often referred to as the Tumor Mutational Burden (TMB), can correlate with the number of neoepitopes it presents. This variability means each person’s tumor has a unique set of neoepitopes.

Dec 10, 2020 06:57 AM

Neoepitopes are a class of major histocompatibility complex (MHC) bounded peptides that arise from tumor-specific mutations.They represent the antigenic determinants of neoantigens. Neoepitopes are recognized by the immune system as targets for T cells and can elicit immune response to cancer.

Neoepitopes are a class of major histocompatibility complex (MHC) bounded peptides that arise from tumor-specific mutations.They represent the antigenic determinants of neoantigens. Neoepitopes are recognized by the immune system as targets for T cells and can elicit immune response to cancer

Epitopes, also referred to as antigenic determinants, are parts of an antigen that are recognized by the immune system. A neoepitope is an epitope the immune system has not encountered before. Therefore it is not subject to tolerance mechanisms of the immune system. As the mutant gene product is only expressed in tumors and is not found in non-cancerous cells, neoepitopes may evoke a vigorous T cell response. Tumor Mutational Burden (TMB, the number of mutations within a targeted genetic region in the cancerous cell's DNA) correlates with the number of neoepitopes, and have been suggested to correlate with patient survival post immunotherapy, although the findings about the neoantigen/immunogenicity association are disputed.

Neoepitopes arise from post-translational modifications. The mRNA translates information from the DNA into polypeptide composed of 20 standard amino acids and then proteins. Several of the standard amino acids can be posttranslationally modified by enzymatic processes, or can be altered through spontaneous (nonenzymatic) biochemical reactions.

There is increasing evidence that immune recognition of neoepitopes produced by cancer-specific mutations is a key mechanism for the induction of immune-mediated tumor rejection. Opportunities for therapeutic targeting of cancer specific neoepitopes are under investigation.